在阿尔茨海默氏病模型中,优化和表征SHIP1对细胞向参与和活动的灵配体
Cynthia D Jesudason1, Claudia Rangel-Barajas2,3, Colin J Beach2
1Lgenia, Fortville, Indiana 46040, United States.
bioRxiv : the preprint server for biology
|January 9, 2026
概括
研究人员开发了一种针对SHIP1 (Src同质性2域含伊诺西5-酸酶1) 的新型化合物,用于潜在的阿尔茨海默病治疗. 这种化合物在小鼠模型中显示大脑透,并减少神经炎症标志物.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- SHIP1 (INPP5D) 是一种脂质酶,调节微质和造血细胞中的免疫信号传递.
- 失调的SHIP1活动与阿尔茨海默病相关的神经炎症过程有关.
研究的目的:
- 为了识别和描述针对SHIP1的新型小分子,与中枢神经系统 (CNS) 接触.
- 在阿尔茨海默病的临床前模型中评估SHIP1向化合物的治疗潜力.
主要方法:
- 使用生物化学和细胞测试的结构-活性关系研究与人类和小鼠SHIP1.1.
- 热转移测定目标接触,脂管测定酸变化,以及微细胞细胞的高含量成像.
- 在口服服化合物后的氨基粉症小鼠模型中的药理动力学和药理动力学评估.
主要成果:
- 一个pyridyl-pyrazole-piperidine支架产生了一种化合物 (32),证明了SHIP1的参与和中枢神经系统的透.
- 化合物32调制下游信号传递 (AKT),改变了类化池,并增强了粉样蛋白残留物的微细胞化.
- 在体内,化合物32在阿尔茨海默病小鼠模型中降低了神经炎症标记物 (IL-1β).
结论:
- 已识别的支架提供了穿透大脑的SHIP1配体,其体内活性已被证明.
- 这些发现支持进一步开发SHIP1抑制剂作为阿尔茨海默氏症和相关神经炎症疾病的治疗策略.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.7K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
相关概念视频
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
